WHO ICTRP trial
Clinical trial to evaluate the feasibility of pegylated liposomal doxorubicin…
EUCTR2014-000842-30-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2014-000842-30-IT |
|---|---|
| Public title | Clinical trial to evaluate the feasibility of pegylated liposomal doxorubicin (Caelyx¿) in women operated for a breast cancer with estrogen receptors expression but either high proliferation rate, or low progesterone receptors expression, or overexpression of HER2. |
| Scientific title | Caelyx¿ as Adjuvant Treatment in Early Stage Luminal B Breast Cancer: a feasibility Phase II Trial - Not applicable |
| Primary sponsor | ISTITUTO EUROPEO DI ONCOLOGIA |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Italy |
| Conditions | Operated breast cancer MedDRA version: 20.0 Level: LLT Classification code 10006190 Term: Breast cancer invasive NOS System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: CAELYX - 2 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO 10 ML USO EV Pharmaceutical Form: Concentrate for solution for infusion |
| Registration date | Jan 26, 2021 |
| Target size | 63 |
| Secondary IDs | IEO62 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: